May 19, 2020 / 02:50PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello, and welcome to day 2 of the UBS Global Healthcare Conference. My name is Navin Jacob. I'm the senior analyst covering large tech pharmaceuticals and smid-cap biotech. Our next presentation or fireside chat is with Eli Lilly. It's my pleasure to have with us Mike Mason, President of Lilly Diabetes, as well as Mike Czapar from the Investor Relations team. Mike and Mike, thank you so much for joining us today. Hope you're both well.
Michael B. Mason - Eli Lilly and Company - Senior VP & President of Lilly Diabetes
Thank you. Yes, we're both healthy and safe.
Questions and Answers:
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap PharmaceuticFantastic. That's great to hear. And so why don't we start at a broad level with a topic that can't be escaped, obviously COVID-19. We'll start
Trustpilot
